Does Unasyn (ampicillin/sulbactam) cover Salmonella infections?

Does Unasyn Cover Salmonella?

Yes, Unasyn (ampicillin/sulbactam) does have activity against Salmonella, but it is NOT a first-line agent and should only be used in specific clinical contexts where the organism is susceptible.

Key Clinical Context

The ampicillin component of Unasyn can treat Salmonella infections when the organism is susceptible, as documented in multiple guidelines 1. However, this is a critical distinction—ampicillin alone (not the combination) is the active component against Salmonella, and sulbactam primarily serves as a beta-lactamase inhibitor for other organisms.

When Unasyn May Be Appropriate for Salmonella

Pediatric Populations

• HIV-exposed infants <3 months and HIV-infected children with severe immunosuppression can receive ampicillin (as part of Unasyn) for Salmonella gastroenteritis to prevent extraintestinal spread 1
• Treatment options include TMP-SMZ, ampicillin, cefotaxime, ceftriaxone, or chloramphenicol 1
• One clinical case series documented successful treatment of salmonellosis with sulbactam/ampicillin in a pediatric patient 2

Pregnant Women

• Ampicillin is listed as an acceptable treatment choice for Salmonella gastroenteritis in pregnancy (along with cefotaxime, ceftriaxone, or TMP-SMZ) to prevent extraintestinal spread that could lead to placental/amniotic fluid infection 1
• Fluoroquinolones should be avoided in pregnancy 1

Long-term Suppression in Children

• For HIV-infected children with Salmonella septicemia requiring chronic suppression, ampicillin can be used if the organism is susceptible, though TMP-SMZ is preferred 3

Critical Limitations and Caveats

First-Line Therapy

Fluoroquinolones (primarily ciprofloxacin 750 mg twice daily for 14 days) are the preferred agents for:

• HIV-infected adults with Salmonella gastroenteritis when treatment is chosen 1
• Long-term suppression of Salmonella septicemia in susceptible organisms 3

Resistance Concerns

• Research shows variable susceptibility patterns: one study found 93.7% of Salmonella Typhimurium isolates were resistant to at least one antibiotic, with multiresistance common 4
• Recent data (2025) shows 27.86% of Salmonella isolates demonstrated resistance to at least one antibiotic, most frequently to tetracycline, ampicillin, and piperacillin 5
• The blaTEM gene (conferring beta-lactam resistance) was detected in 16.18% of strains 5

FDA Labeling

The official Unasyn FDA label does NOT list Salmonella as an indicated organism 6. The label specifically covers:

• Skin/soft tissue infections
• Intra-abdominal infections
• Gynecological infections

The label states: "infections caused by ampicillin-susceptible organisms are also amenable to treatment with UNASYN due to its ampicillin content" 6, which technically includes susceptible Salmonella, but this is not an FDA-approved indication.

Practical Algorithm for Decision-Making

1. Is this a Salmonella infection requiring treatment?

   • Most immunocompetent adults with gastroenteritis do NOT need treatment
   • Treat if: septicemia, severe immunosuppression (HIV with CD4 <200), pregnancy, infants <3 months, or invasive disease

2. Can fluoroquinolones be used?

   • If YES → Use ciprofloxacin (preferred agent)
   • If NO (pregnancy, children, resistance) → Consider alternatives

3. Is susceptibility testing available?

   • If ampicillin-susceptible → Unasyn could be used
   • If resistant or unknown → Choose ceftriaxone, cefotaxime, or TMP-SMZ instead

4. What is the clinical setting?

   • Gastroenteritis in special populations: ampicillin acceptable if susceptible
   • Septicemia/bacteremia: fluoroquinolones strongly preferred
   • Chronic suppression: fluoroquinolones first-line; ampicillin only if susceptible

Bottom Line

Unasyn should not be considered a reliable empiric choice for Salmonella infections given increasing ampicillin resistance rates and the availability of superior alternatives (fluoroquinolones, third-generation cephalosporins). It may be used in susceptible isolates in specific populations (pregnant women, young children) where fluoroquinolones are contraindicated, but always obtain susceptibility testing before relying on ampicillin-based therapy for Salmonella.